Dimensional Fund Advisors LP Has $231.20 Million Position in Novo Nordisk A/S (NYSE:NVO)

Dimensional Fund Advisors LP trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 7.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,619,739 shares of the company’s stock after selling 128,604 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Novo Nordisk A/S were worth $231,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Aveo Capital Partners LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $205,000. 9258 Wealth Management LLC grew its holdings in Novo Nordisk A/S by 4.0% in the fourth quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after purchasing an additional 97 shares during the period. Rollins Financial increased its stake in Novo Nordisk A/S by 10.4% in the fourth quarter. Rollins Financial now owns 3,894 shares of the company’s stock valued at $403,000 after purchasing an additional 368 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Novo Nordisk A/S by 38.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after purchasing an additional 26,067 shares during the period. Finally, Gryphon Financial Partners LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $237,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $132.09 on Thursday. Novo Nordisk A/S has a 1-year low of $86.96 and a 1-year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The stock has a market cap of $592.76 billion, a PE ratio of 45.55, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The stock’s fifty day simple moving average is $133.52 and its two-hundred day simple moving average is $133.19.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.06). The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, analysts forecast that Novo Nordisk A/S will post 3.11 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is 24.83%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NVO. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday. Finally, Argus raised their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $145.17.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.